• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.

作者信息

Jew Olivia S, Liu Winston W, Stamey Christopher, Kheterpal Meenal, Myers Sarah A, Ellis Matthew J, Byrns Jennifer, Wheless Lee, Whitley Melodi Javid

机构信息

Department of Dermatology, Duke University Health System, Durham, North Carolina.

Duke University School of Medicine, Durham, North Carolina.

出版信息

J Am Acad Dermatol. 2024 Oct;91(4):720-722. doi: 10.1016/j.jaad.2024.05.068. Epub 2024 Jun 4.

DOI:10.1016/j.jaad.2024.05.068
PMID:38844009
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11416314/
Abstract
摘要

相似文献

1
De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.与标准疗法相比，肾移植受者使用从头开始的贝拉西普并不能降低皮肤癌的发生率。
J Am Acad Dermatol. 2024 Oct;91(4):720-722. doi: 10.1016/j.jaad.2024.05.068. Epub 2024 Jun 4.
2
Belatacept reduces skin cancer risk in kidney transplant recipients.贝拉西普可降低肾移植受者患皮肤癌的风险。
J Am Acad Dermatol. 2020 Apr;82(4):996-998. doi: 10.1016/j.jaad.2019.09.070. Epub 2019 Oct 4.
3
Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.肾移植受者转换为贝利尤单抗为基础的免疫抑制治疗后的长期结局。
Clin J Am Soc Nephrol. 2024 May 1;19(5):628-637. doi: 10.2215/CJN.0000000000000411. Epub 2024 Feb 22.
4
Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.微血管炎症是钙调磷酸酶抑制剂方案转换为贝利尤单抗方案后非常晚才发生的肾移植受者的一个风险因素。
BMC Nephrol. 2020 Aug 20;21(1):354. doi: 10.1186/s12882-020-01992-6.
5
Belatacept Versus Tacrolimus for Kidney Transplant Recipients of Deceased Donors With Acute Kidney Injury: US National Database Study.贝拉西普与他克莫司用于急性肾损伤的已故供体肾移植受者：美国国家数据库研究
Transplantation. 2025 Apr 1;109(4):691-700. doi: 10.1097/TP.0000000000005196. Epub 2024 Sep 4.
6
Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States.美国肾移植受者中新型贝拉西普的时间趋势及当前使用情况。
Clin Transplant. 2022 Mar;36(3):e14531. doi: 10.1111/ctr.14531. Epub 2021 Nov 29.
7
Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients.贝拉西普预防成人肾移植受者器官排斥反应。
Expert Rev Clin Pharmacol. 2016;9(2):215-27. doi: 10.1586/17512433.2016.1112736. Epub 2015 Dec 22.
8
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.在肾移植受者中从钙调磷酸酶抑制剂转换至贝利尤单抗后的 3 年安全性和疗效结局：一项 2 期随机试验的结果。
Am J Kidney Dis. 2017 May;69(5):587-594. doi: 10.1053/j.ajkd.2016.09.021. Epub 2016 Nov 23.
9
Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.巴利昔单抗治疗肾移植后钙调磷酸酶抑制剂治疗失败后的挽救性免疫抑制。
Am J Transplant. 2019 Aug;19(8):2342-2349. doi: 10.1111/ajt.15319. Epub 2019 Mar 12.
10
Belatacept for kidney transplant recipients.用于肾移植受者的贝拉西普。
Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD010699. doi: 10.1002/14651858.CD010699.pub2.

引用本文的文献

1
Belatacept and non-melanoma skin cancer risk in kidney transplant recipients: a narrative review from a mechanistic and clinical perspective.贝拉西普与肾移植受者非黑色素瘤皮肤癌风险：基于机制和临床视角的叙述性综述
BMC Nephrol. 2025 Aug 23;26(1):487. doi: 10.1186/s12882-025-04373-z.
2
Immunosuppressants/Immunomodulators and Malignancy.免疫抑制剂/免疫调节剂与恶性肿瘤
J Clin Med. 2025 Jul 21;14(14):5160. doi: 10.3390/jcm14145160.
3
Cancer Screening and Cancer Treatment in Kidney Transplant Recipients.肾移植受者的癌症筛查和癌症治疗。

本文引用的文献

1
Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future.共刺激阻断与实体器官移植：过去、现在与未来
Kidney Int Rep. 2023 Sep 3;8(12):2529-2545. doi: 10.1016/j.ekir.2023.08.037. eCollection 2023 Dec.
2
Differences in Skin Cancer Rates by Transplanted Organ Type and Patient Age After Organ Transplant in White Patients.白人患者中，不同类型移植器官和患者年龄对皮肤癌发病率的影响。
JAMA Dermatol. 2022 Nov 1;158(11):1287-1292. doi: 10.1001/jamadermatol.2022.3878.
3
Cohort and nested case-control study of cutaneous squamous cell carcinoma in solid organ transplant recipients, by medication.
Kidney360. 2024 Oct 1;5(10):1569-1583. doi: 10.34067/KID.0000000000000545.
4
Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression.实体器官移植相关免疫抑制患者的皮肤鳞状细胞癌
Cancers (Basel). 2024 Sep 4;16(17):3083. doi: 10.3390/cancers16173083.
按用药情况对实体器官移植受者皮肤鳞状细胞癌进行队列研究和巢式病例对照研究。
J Am Acad Dermatol. 2022 Mar;86(3):598-606. doi: 10.1016/j.jaad.2021.07.065. Epub 2021 Aug 9.
4
Belatacept reduces skin cancer risk in kidney transplant recipients.贝拉西普可降低肾移植受者患皮肤癌的风险。
J Am Acad Dermatol. 2020 Apr;82(4):996-998. doi: 10.1016/j.jaad.2019.09.070. Epub 2019 Oct 4.
5
Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study.预测器官移植受者的皮肤癌：使用多中心队列研究数据开发 SUNTRAC 筛查工具。
Transpl Int. 2019 Dec;32(12):1259-1267. doi: 10.1111/tri.13493. Epub 2019 Oct 7.